



UvA-DARE (Digital Academic Repository)

Abdominal aortic aneurysms

The quest for meaningful biomarkers and opportunities to improve surgical care

Jalalzadeh, H.

Publication date

2019

Document Version

Other version

License

Other

[Link to publication](#)

Citation for published version (APA):

Jalalzadeh, H. (2019). *Abdominal aortic aneurysms: The quest for meaningful biomarkers and opportunities to improve surgical care*. [Thesis, fully internal, Universiteit van Amsterdam].

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.




CHAPTER 8

Nationwide analysis of patients undergoing iliac artery aneurysm repair in the Netherlands

Submitted

H. Jalalzadeh, R. Indrakusuma, M.J.W. Koelemay, R. Balm



ABSTRACT

Objectives

The new 2019 guideline of the European Society for Vascular Surgery (ESVS) recommends to consider elective iliac artery aneurysm (eIAA) repair when the iliac diameter exceeds 3.5 cm. This recommendation is based on low-quality evidence. The current study assessed diameters at time of eIAA repair and ruptured IAA (rIAA) repair, and compared clinical outcomes after open surgical repair (OSR) and endovascular aneurysm repair (EVAR).

Methods

This retrospective observational study used the nationwide Dutch Surgical Aneurysm Audit (DSAA) registry and included all patients who underwent primary IAA repair between 2014 and 2018. Diameters at time of eIAA and rIAA repair were obtained from the DSAA registry. Patient characteristics and outcomes of OSR and EVAR were compared with appropriate statistical tests.

Results

A total of 851 patients were included. eIAA repair was carried out in 713 patients, rIAA repair in 102, and symptomatic IAA repair in 36. OSR was performed in 205, EVAR in 618, and hybrid repairs and conversions in 28. The median maximal IAA diameter at time of eIAA and rIAA repair was 43 (IQR 38-50) mm and 68 (IQR 58-85) mm, respectively. Mortality was 1.3% (95% CI 0.7-2.4) after eIAA repair and 25.5% (95% CI 18.0-34.7) after rIAA repair. Mortality was not significantly different between OSR and EVAR subgroups. Patients undergoing elective OSR had significantly more complications compared to EVAR (intraoperative: 9.8% vs 3.6%, postoperative: 34.0% vs 13.8% respectively).

Conclusions

In the Netherlands, most eIAA repairs are performed at diameters larger than recommended by the ESVS guideline. This appears to be safe, as the median IAA diameter at time of rupture is 2.5 cm larger than at time of elective repair. The results indicate that the threshold diameter for eIAA repair could possibly be raised to larger diameters.

INTRODUCTION

Iliac artery aneurysm (IAA) is a condition that accounts for a small proportion of all intra-abdominal aneurysms. Approximately 20% of patients with abdominal aortic aneurysms (AAAs) have concomitant IAA.¹ Similar to AAAs, IAAs are often operated electively to prevent future rupture. The introduction of endovascular aneurysm repair (EVAR) has resulted in a significant increase of elective IAA (eIAA) repair in recent years.²

No IAA-specific trials have been conducted to date. The small body of evidence regarding IAA management is in sharp contrast to that of AAA. Outcomes after AAA repair are well known and trials have demonstrated that it is safe to wait with elective AAA repair in men until a maximal diameter of 5.5 cm is reached.³ As a result, 5.5 cm is widely used as a threshold diameter for elective AAA repair.^{4,5} With respect to IAA, the clinical outcomes of patients have not been described extensively and there is no solid evidence with regard to a threshold diameter for elective repair. The recent 2019 guideline on abdominal aorto-iliac artery aneurysms from the European Society for Vascular Surgery (ESVS) recommends to consider eIAA repair when the iliac artery diameter exceeds 3.5 cm.⁵ This recommendation is based on evidence of low quality (level C) and does not make a distinction between aneurysms of the common, external, or internal iliac artery (CIA, EIA, IIA, respectively). Others have suggested that the threshold diameter for eIAA repair should be raised to 4 cm.⁶

We used the Dutch Surgical Aneurysm Audit (DSAA) registry to evaluate the indications and outcomes of IAA surgery on a national level in the Netherlands.⁷ The primary objective of this study was to determine the maximal diameters of IAA at time of eIAA repair and ruptured IAA (rIAA) repair. Other objectives were to present clinical outcomes after IAA repair, to compare outcomes after open surgical repair (OSR) and EVAR, and to determine risk factors for postoperative mortality.

MATERIALS AND METHODS

Study design and setting

This retrospective observational study used prospectively collected data from the DSAA registry, which is a nationwide prospective registry of all patients undergoing aortic or iliac aneurysm repair in the Netherlands. DSAA is one of the healthcare registries of the Dutch Institute of Clinical Auditing.⁷ Registration of patients in the DSAA registry is mandatory for all hospitals carrying out aneurysm repair. Vascular surgeons prospectively register patients and their characteristics and outcomes in this registry. The scientific board of DSAA approved the study protocol (DSAA201707) prior to release of the data. This study included patients who underwent repair from 01-01-2014 until 01-01-2018. Patient consent was not required because the data was anonymized. This study complied with the Declaration of Helsinki and was carried out in accordance with the STROBE statement.⁸

Participants and study size

All patients who were registered in the DSAA for primary IAA repair were eligible for inclusion in this study. Patients were excluded when predefined variables labelled as essential were missing. These essential variables were age, sex, repair method (i.e. OSR, EVAR), and urgency of repair (elective, ruptured, or symptomatic non-ruptured IAA).

Endpoints

The primary endpoint was maximal IAA diameter (in mm) at time of IAA repair. Secondary endpoints were the urgency of repair, method of repair, postoperative mortality, 30-day complications, and baseline patient characteristics (including age, sex and comorbidity). Urgency of repair was categorized as elective, ruptured, or symptomatic non-ruptured IAA (including repair of embolizing IAA). Postoperative mortality was defined as the combined 30-day and in-hospital mortality. The method of repair was categorized as OSR, EVAR (including iliac branched devices), hybrid repair or primary conversion. Definitions for the postoperative complications are listed in Supplemental table 1. Baseline patient characteristics and comorbidities were registered in the DSAA in accordance with the categorizations of the Physiological and Operative Severity Score for the enumeration of Mortality and morbidity (POSSUM) score, a mortality risk prediction model for surgical patients.⁹ The anatomical location of the IAA (CIA, EIA or IAA) was not registered in the DSAA and could not be analysed.

Statistical analysis

Missing data were not imputed. Categorical data are reported as numbers and percentages with 95% confidence intervals (CI). Normally distributed continuous data are reported as mean \pm standard deviation (SD). Data with skewed distribution are reported as median

with interquartile range (IQR). Differences between patients undergoing OSR and EVAR were tested with the Fisher's exact test for categorical variables, and with the unpaired t-test or Mann-Whitney U test for continuous variables. The test choice was based on the distribution of the data, which was tested with the Shapiro-Wilk test. Risk factors for postoperative mortality were identified by applying the same method. Differences were calculated between patients who did and did not survive the hospital stay. This was done separately for both eIAA and rIAA repair. A multivariable logistic regression analysis was not carried out because the absolute mortality numbers were low, and because some baseline variables were so rare that odds ratios could not be calculated, or were accompanied by very wide confidence intervals. All statistical analyses were carried out using IBM SPSS Statistics version 24 (IBM Inc., Armonk, NY, USA). A p value of $< .05$ was considered statistically significant.

RESULTS

Participants

The DSAA registry database contained 974 patients who underwent IAA repair between 01-01-2014 and 01-01-2018. A total of 851 patients were included in this study after exclusion of 119 patients who underwent revision surgery, and four patients with missing essential variables (age, sex, repair method and repair urgency – in one respectively). Some 91% of patients (n=778) were male and the mean age was 71.6 ± 8.9 years (Table 1). Other patient characteristics are listed in Supplemental table 2.

A total of 713 patients (84%) underwent eIAA repair, 102 underwent rIAA repair, 36 underwent sIAA repair. The method of repair was OSR in 205 patients, EVAR in 618 (including 100 iliac branched devices), and other methods in 28 (12 hybrid repairs, 5 primary conversions and 11 others). Patients undergoing rIAA repair were significantly older than patients undergoing eIAA repair (median 74 vs 72 years respectively; Table 1; $p = 0.007$). Patients who underwent EVAR were treated with devices of Medtronic (n=229), Gore (n=196), Cook (n=92), Vascutek (n=38), Endologix (n=30), and others (n=33).

Main outcomes

IAA diameter at time of repair

Elective IAA repair

Diameter data was available for 706 of 713 patients undergoing eIAA repair. The median maximal IAA diameter of 706 patients was 43 (IQR 38 - 50) mm. The diameters were not significantly different between OSR and EVAR subgroups (45 mm vs 43 mm in 152 and 531 patients respectively, $p = 0.470$; Table 1). A total of 72 of 706 IAAs (10.2%) were smaller than 35 mm at time of elective repair (Figure 1, Supplemental table 3).

Table 1. Characteristics of 851 patients undergoing primary IAA repair

| | Total (n = 851) | Elective (n = 713) | Rupture (n = 102) | Symptomatic (n = 36) | Total missing |
|----------------------------------------|-------------------------------|------------------------------|--------------------------------|-------------------------------|------------------|
| Age | 71.6 ± 8.9 72 (66 - 78) | 71.2 ± 8.7 72 (66 - 77) | 74.0 ± 8.5 74 (68 - 81) | 71.3 ± 12.9 73.5 (66 - 80) | 0 |
| Male sex | 778 (91.4%) | 656 (92.0%) | 91 (89.2%) | 31 (86.1%) | 0 |
| Cardiac disease | 447 (53.7%) | 378 (53.7%) | 50 (53.8%) | 19 (54.3%) | 19 |
| Pulmonary disease | 173 (20.9%) | 153 (21.6%) | 13 (14.6%) | 7 (21.9%) | 23 |
| Preoperative serum creatinine (mmol/L) | 103.5 ± 61.6 90 (77 - 110) | 99.9 ± 60.5 88 (76 - 105) | 127.4 ± 56.7 116 (93 - 150) | 107.9 ± 81.1 89 (77 - 116) | 23 |
| IAA diameter (mm) | | | | | |
| - Total | 48.6 ± 15.5 45 (38 - 54) | 45.4 ± 11.5 43 (38 - 50) | 69.0 ± 21.5 68 (58 - 85) | 60.4 ± 21.2 60 (42 - 75) | 20 |
| - EVAR | 47.6 ± 14.1 45 (39 - 52) | 45.2 ± 10.5 43 (38 - 50) | 67.6 ± 22.3 61 (58 - 84) | 61.0 ± 22.5 58 (43 - 74) | 16 |
| - Open repair (OSR) | 52.2 ± 18.7 48 (38 - 64) | 46.6 ± 14.4 45 (37 - 52) | 72.3 ± 19.7 71 (60 - 87) | 59.0 ± 19.0 65 (38 - 78) | 4 |
| Repair method | | | | | |
| - EVAR | 618 (72.6%) | 536 (75.2%) | 57 (55.9%) | 25 (69.4%) | 0 |
| - Open repair (OSR) | 205 (24.1%) | 154 (21.6%) | 40 (39.2%) | 11 (30.6%) | 0 |
| - Other | 28 (3.3%) | 23 (3.3%) | 5 (4.9%) | 0 | 0 |

Continuous variables are presented as mean ± standard deviation and median (interquartile range).

Ruptured IAA repair

Diameter data was available for 90 of 102 patients undergoing rIAA repair. The median maximal diameter of 90 patients was 68 (IQR 58 - 85) mm and was not significantly different between OSR and EVAR subgroups (71 mm vs 61 mm in 38 and 47 patients respectively, $p = 0.313$). At time of rupture, 4 of 90 IAAs (4.4%) were < 30 mm, and 5 IAAs (5.5%) were 30 - 40 mm (Figure 1, Supplemental table 3). IAA diameters were significantly larger at time of rupture than at time of elective repair ($p < 0.001$).

Sex differences

Diameters at time of surgery were not different between men and women – both for eIAA repair (median 43.0 mm vs 42.5 mm, in 650 and 56 patients respectively, $p = 0.412$), and for rIAA repair (median 68.5 vs 63.0 mm, in 80 and 10 patients respectively, $p = 0.719$).

Postoperative outcomes

Elective IAA repair

Mortality was 1.3% (9/713; 95% CI 0.7% - 2.4%) after eIAA repair and was not




Figure 1. Distribution of IAA diameter at time of elective IAA repair and ruptured IAA repair

significantly different between OSR and EVAR subgroups (2.6% vs 0.9% respectively; $p = 0.118$). Complications occurred significantly more often after OSR compared to EVAR (intraoperative complications: 9.8% vs 3.6%, $p = 0.005$; postoperative complications: 34.0% vs 13.8%, $p < 0.001$). In total, 197 postoperative complications occurred in 130 patients (Table 2). The most frequent complications were arterial occlusions (in 25) and

Table 2. Postoperative outcomes after IAA repair

| | Elective IAA repair | | | |
|---------------------------------------------------------|-------------------------|-------------------------|--------------------------|---------|
| | Total* | EVAR | OSR | p value |
| Mortality | 9/713 (1.3%) | 5/536 (0.9%) | 4/154 (2.6%) | 0.118 |
| Patients with intraoperative Complications [†] | 40/703 (5.7%) | 19/527 (3.6%) | 15/153 (9.8%) | 0.005 |
| Patients with postoperative complications [†] | 130/712 (18.3%) | 74/536 (13.8%) | 52/153 (34.0%) | < 0.001 |
| Postoperative complications | 197 | 102 | 86 | - |
| - Abdominal | 23 | 5 | 16 | - |
| - Arterial occlusion | 25 | 16 | 9 | - |
| - Prosthesis-related | 15 | 15 | 0 | - |
| - Wound | 12 | 5 | 4 | - |
| - Cardiac | 18 | 9 | 8 | - |
| - Pulmonary | 23 | 8 | 15 | - |
| - Neurological | 11 | 5 | 5 | - |
| - Renal | 8 | 2 | 5 | - |
| - Rebleeding | 5 | 3 | 2 | - |
| - Infection | 12 | 7 | 5 | - |
| - Other | 45 | 27 | 17 | - |
| Total admission days ^x | 5.6 ± 20.7 3 (2 - 5) | 4.5 ± 23.1 2 (2 - 3) | 9.7 ± 10.3 7 (5 - 10) | <0.001 |
| ICU admission days | 0.9 ± 4.3 0 (0 - 1) | 0.3 ± 2.1 0 (0 - 0) | 2.8 ± 7.9 1 (1 - 2) | <0.001 |
| Reinterventions within 30 days | 46/455 (10.1%) | 26/334 (7.8%) | 19/101 (18.8%) | 0.003 |
| Readmissions | 50/713 (7.0%) | 38/536 (7.1%) | 11/154 (7.1%) | 1 |

* The 'Total' columns include other methods of repair than OSR and EVAR only (i.e. hybrid repair and primary conversion). [†] The sum of complications is more than the number of patients with complications. ►

abdominal and pulmonary complications (both in 23). The number of hospital admission days were significantly higher after OSR (median 7 vs 2 days; $p < 0.001$). Similar differences between OSR and EVAR were observed for ICU admission days ($p < 0.001$) and reintervention rates ($p = 0.003$; Table 2).

Ruptured IAA repair

Mortality after rIAA repair was 25.5% (26/102; 95% CI 18.0% - 34.7%). The difference between OSR and EVAR was not statistically significant (32.5% vs 17.5% respectively, $p = 0.097$). A total of 100 postoperative complications occurred in 57 patients. Intra- and postoperative complication rates were not statistically different between OSR and EVAR subgroups. However, the number of hospital admission days was significantly higher after

| Ruptured IAA repair | | | | Symptomatic IAA repair | | | |
|---------------------------|-------------------------|----------------------------|---------|-------------------------|------------------------|---------------------------|---------|
| Total* | EVAR | OSR | p value | Total* | EVAR | OSR | p value |
| 26/102 (25.5%) | 10/57 (17.5%) | 13/40 (32.5%) | 0.097 | 2/36 (5.6%) | 2/25 (8.0%) | 0/11 (0%) | 1 |
| 16/100 (16.0%) | 7/56 (12.5%) | 8/39 (20.5%) | 0.392 | 1/36 (2.8%) | 0/30 (0%) | 1/11 (9.1%) | 0.268 |
| 57/101 (56.4%) | 27/56 (48.2%) | 27/40 (67.5%) | 0.065 | 12/36 (33.3%) | 9/25 (36.0%) | 3/11 (27.3%) | 0.715 |
| 100 | 47 | 47 | - | 19 | 13 | 5 | - |
| 13 | 5 | 8 | - | 4 | 3 | 1 | - |
| 6 | 4 | 1 | - | 3 | 1 | 2 | - |
| 2 | 1 | 1 | - | 0 | 0 | 0 | - |
| 1 | 1 | 0 | - | 1 | 1 | 0 | - |
| 11 | 4 | 5 | - | 1 | 1 | 0 | - |
| 19 | 8 | 9 | - | 5 | 4 | 1 | - |
| 5 | 3 | 2 | - | 1 | 1 | 0 | - |
| 11 | 5 | 5 | - | 2 | 1 | 0 | - |
| 1 | 0 | 1 | - | 1 | 1 | 0 | - |
| 10 | 6 | 4 | - | 0 | 0 | 0 | - |
| 21 | 10 | 11 | - | 1 | 0 | 1 | - |
| 18.4 ± 44.6 8 (6 - 16) | 19 ± 55.1 7 (5 - 13) | 17.6 ± 20.3 10 (8 - 20) | 0.003 | 8.7 ± 9.3 5 (2 - 11) | 6.7 ± 9.5 3 (2 - 7) | 12.9 ± 7.6 12 (7 - 19) | 0.002 |
| 4.2 ± 9.4 2 (1 - 4) | 3.0 ± 5.7 2 (1 - 3) | 6.2 ± 13.3 2 (1 - 5) | 0.067 | 1.7 ± 3.9 0 (0 - 2) | 0.7 ± 1.8 0 (0 - 1) | 4.0 ± 6.1 2 (1 - 3) | 0.004 |
| 14/67 (24.1%) | 7/37 (18.9%) | 6/25 (24.0%) | 0.753 | 2/27 (7.4%) | 2/19 (10.5%) | 0/8 (0%) | 1 |
| 10/102 (9.8%) (8.8%) | 5/57 (8.8%) | 5/40 (12.5%) | 0.736 | 3/36 (8.3%) | 3/25 (12%) | 0/11 (0%) | 0.538 |

* Only includes patients surviving hospital stay. Continuous variables are presented as mean ± standard deviation and median (interquartile range).

OSR compared to EVAR (median 10 vs 7 days, $p = 0.003$). Outcomes after symptomatic (non-ruptured) IAA repair are also listed in Table 2. The small number of patients and events in the male and female subgroups did not allow other statistical assessments of mortality differences between men and women (Supplemental table 4).

Risk factors for mortality

None of the available baseline patient characteristics or preoperative measurements was associated with mortality after eIAA repair. The single measurement significantly associated with mortality after rIAA repair was preoperative serum creatinine ($p = 0.003$) (Supplemental table 5).

DISCUSSION

This nationwide analysis of surgery for IAA in the Netherlands demonstrated that elective IAA repair was carried out at a median maximal diameter of 43 mm. IAAs ruptured at a median maximal diameter of 68 mm. Mortality was 1.3% after elective repair and 25.5% after ruptured IAA repair. Mortality was not significantly different between OSR and EVAR subgroups. Patients undergoing elective OSR suffered from significantly more intra- and postoperative complications compared to patients undergoing elective EVAR.

With a median IAA diameter of 43 mm at time of elective repair, most patients in the Netherlands are electively operated when the recommended threshold diameter of 35 mm is exceeded. This appears to be safe, as the median IAA diameter at time of rupture is 2.5 cm larger than at time of elective repair. This also suggests that the threshold diameter for eIAA repair could be raised to larger diameters. Currently, only 10% of patients are operated before the IAA reaches a diameter of 35 mm. This is in line with practice in other countries. Boules et al. reported a mean diameter of 42 mm at time of elective repair in the United States between 1995 and 2004.¹⁰ More recently, a survey among vascular surgeons from the United Kingdom revealed that two-third of surgeons would wait until a CIA aneurysm reached 40 mm in diameter before considering elective repair.⁶

The large difference between IAA diameter at time of eIAA repair and at time of rIAA repair supports the recent raise of the threshold diameter from 3.0 to 3.5 cm by the ESVS.⁵ This is also confirmed when the current results are compared to previous AAA studies. A recent AAA study with DSAA data (of 1331 men) demonstrated that 8% of AAAs rupture below the threshold diameter of 5.5 cm.¹¹ If that 8th percentile would be translated to the current cohort of 90 ruptured IAAs, it would correspond to an IAA-equivalent diameter of 34 mm (Supplemental table 3). A 34-mm threshold for eIAA repair would result in 8% of IAAs rupturing below the threshold diameter. That would be equal to the currently accepted risk of rupture for AAA. This comparison between IAA and AAA only serves for hypothesis-generating purposes, and is only valid if the ratio between operation risk and rupture risk is similar for IAA and AAA. The peri-operative mortality risk in our study was 2.6% and 0.9% after elective OSR and EVAR respectively, which is slightly lower than the short-term mortality of 5.0 % and 0.9 % after elective OSR and EVAR of AAA in the Netherlands.¹² With regard to IAA rupture risk, evidence is unfortunately limited to very few studies that assessed expansion rates.^{13,14} These studies did not detect sufficient ruptures to allow assessment of rupture risk. As randomized controlled trials on IAA are challenging to perform, evidence remains limited to observational studies and comparisons with similar conditions such as AAA.

A remarkable result of the current study was the good outcome after elective EVAR. Postoperative mortality was around 1%, and patients had significantly fewer complications and shorter hospital admissions compared to OSR. Our findings correspond to results from previous studies. Buck et al. consulted the Nationwide Inpatient Sample database from the United States (with 9016 elective EVARs for IAA) and demonstrated an in-hospital mortality of 0.5%, a complication rate of 6.7%, and a median hospital stay of 2.3 days after elective EVAR for isolated IAA.² Other smaller studies found similar results after EVAR and OSR.^{10,15-18} However, as long-term outcomes after IAA repair are largely unknown, it remains premature to suggest an EVAR-first policy for all patients with suitable anatomy.

Strengths and limitations

The strength of this study lies in the large sample size and the national coverage. It is the largest study to date that has reported diameters at time of IAA repair. Nevertheless, this study is subject to some major limitations. As other retrospective studies using administrative databases, there is a possibility of coding errors and missing data. Furthermore, the included patients were registered for undergoing primary IAA repair, and not for undergoing isolated IAA repair. Therefore, the proportion of patients undergoing concomitant AAA repair is unknown. The unavailability of some relevant and interesting data was another limitation. This prevented us from characterizing the cohort in more detail. The most important unavailable variable was the aneurysm location – i.e. CIA, EIA or IIA. CIAs with normal anatomy have diameters that are two times larger than IAA.¹⁹ Ideally, the suggested threshold diameter would therefore be tailored to aneurysms of specific iliac locations. Our current study could unfortunately not make this anatomic distinction – similar to the ESVS guideline that only provided recommendations for IAA in general.⁵ Another limitation was posed by the low absolute mortality rates and some infrequent baseline variables (Supplemental table 2). As a consequence, we only identified one baseline characteristic (i.e. serum creatinine prior to rIAA repair) that was significantly associated with postoperative mortality. In addition, we were unable to carry out a multivariable logistic regression analysis that could identify independent risk factors for mortality. Another limitation was the fact that DSAA only consists of patients who have undergone repair. Diameters at time of rupture are therefore unknown for patients who are not operated for ruptured IAA. Furthermore, the DSAA only contains outcomes up to 30 days after IAA repair. Mid-term and long-term outcomes of this cohort are therefore unknown. Information on endoleaks, graft patency and reinterventions is needed to determine all benefits and harms of OSR and EVAR, which in turn are needed to determine the best treatment strategy for patients with IAA.

Future perspectives

Since no IAA-specific trials are expected in the near future, evidence for clinical management comes from the results of observational studies. Large registries that include both postoperative outcomes and IAA diameters could provide data for these future studies. With statistical methods such as standardization or inverse probability weighting, trials can be mimicked to estimate causal effects.²⁰ Yet, this would require a larger amount of patient-specific data than available for the current study. Furthermore, considering the positive outcomes after EVAR, more research should be conducted on improving EVAR-suitability. Future studies should also investigate the long-term outcomes after IAA repair – and EVAR specifically – since the long-term outcomes after IAA repair are unknown.

ACKNOWLEDGMENTS

The authors thank all collaborators of the Dutch Society for Vascular Surgery (NVvV) who registered the patients and outcome data in the DSAA database.

Collaborators

Van den Akker LH, Van den Akker PJ, Akkersdijk GJ, Akkersdijk GP, Akkersdijk WL, van Andringa de Kempnaer MG, Arts CH, Avontuur JA, Baal JG, Bakker OJ, Balm R, Barendregt WB, Bender MH, Bendermacher BL, van den Berg M, Berger P, Beuk RJ, Blankensteijn JD, Bleker RJ, Bockel JH, Bodegom ME, Bogt KE, Boll AP, Booster MH, Borger van der Burg BL, de Borst GJ, Bos- van Rossum WT, Bosma J, Botman JM, Bouwman LH, Breek JC, Brehm V, Brinckman MJ, van den Broek TH, Brom HL, de Bruijn MT, de Bruin JL, Brummel P, van Brussel JP, Buijk SE, Buimer MG, Burger DH, Buscher HC, den Butter G, Cancrinus E, Castenmiller PH, Cazander G, Coveliers HM, Cuypers PH, Daemen JH, Dawson I, Derom AF, Dijkema AR, Diks J, Dinkelman MK, Dirven M, Dolmans DE, van Doorn RC, van Dortmont LM, van der Eb MM, Eefting D, van Eijck GJ, Elshof JW, Elsman BH, van der Elst A, van Engeland MI, van Eps RG, Faber MJ, de Fijter WM, Fioole B, Fritschy WM, Geelkerken RH, van Gent WB, Glade GJ, Govaert B, Groenendijk RP, de Groot HG, van den Haak RF, de Haan EF, Hajer GF, Hamming JF, van Hattum ES, Hazenberg CE, Hedeman Joosten PP, Helleman JN, van der Hem LG, Hendriks JM, van Herwaarden JA, Heyligers JM, Hinnen JW, Hissink RJ, Ho GH, den Hoed PT, Hoedt MT, van Hoek F, Hoencamp R, Hoffmann WH, Hoksbergen AW, Hollander EJ, Huisman LC, Hulsebos RG, Huntjens KM, Idu MM, Jacobs MJ, van der Jagt MF, Jansbeken JR, Janssen RJ, Jiang HH, de Jong SC, Jongkind V, Kapma MR, Keller BP, Khodadade Jahrome A, Kievit JK, Klemm PL, Klinkert P, Knippenberg B, Koedam NA, Koelemay MJ, Kolkert JL, Koning GG, Koning OH,

Krasznaï AG, Krol RM, Kropman RH, Kruse RR, van der Laan L, van der Laan MJ, van Laanen JH, Lardenoye JH, Lawson JA, Legemate DA, Leijdekkers VJ, Lemson MS, Lensvelt MM, Lijkwan MA, Lind RC, van der Linden FT, Liqui Lung PF, Loos MJ, Loubert MC, Mahmoud DE, Manshanden CG, Mattens EC, Meerwaldt R, Mees BM, Metz R, Minnee RC, de Mol van Otterloo JC, Moll FL, Montauban van Swijndregt YC, Morak MJ, van de Mortel RH, Mulder W, Nagesser SK, Naves CC, Nederhoed JH, Nevenzel-Putters AM, de Nie AJ, Nieuwenhuis DH, Nieuwenhuizen J, van Nieuwenhuizen RC, Nio D, Oomen AP, Oranen BI, Oskam J, Palamba HW, Peppelenbosch AG, van Petersen AS, Peterson TF, Petri BJ, Pierie ME, Ploeg AJ, Pol RA, Ponfoort ED, Poyck PP, Prent A, ten Raa S, Raymakers JT, Reichart M, Reichmann BL, Reijnen MM, Rijbroek A, van Rijn MJ, de Roo RA, Rouwet EV, Rupert CG, Saleem BR, van Sambeek MR, Samyn MG, van 't Sant HP, van Schaik J, van Schaik PM, Scharn DM, Scheltinga MR, Schepers A, Schlejen PM, Schlosser FJ, Schol FP, Schouten O, Schreinemacher MH, Schreve MA, Schurink GW, Sikkink CJ, Siroen MP, te Slaa A, Smeets HJ, Smeets L, de Smet AA, de Smit P, Smit PC, Smits TM, Snoeijs MG, Sondakh AO, van der Steenhoven TJ, van Sterkenburg SM, Stigter DA, Stigter H, Strating RP, Stultiëns GN, Sybrandy JE, Teijink JA, Telgenkamp BJ, Testroote MJ, The RM, Thijsse WJ, Tielliu IF, van Tongeren RB, Toorop RJ, Tordoir JH, Tournoij E, Truijers M, Türkcan K, Tutein Nolthenius RP, Ünlü Ç, Vafi AA, Vahl AC, Veen EJ, Veger HT, Veldman MG, Verhagen HJ, Verhoeven BA, Vermeulen CF, Vermeulen EG, Vierhout BP, Visser MJ, van der Vliet JA, Vlijmen - van Keulen CJ, Voesten HG, Voorhoeve R, Vos AW, de Vos B, Vos GA, Vriens BH, Vriens PW, de Vries AC, de Vries JP, de Vries M, van der Waal C, Waasdorp EJ, Wallis de Vries BM, van Walraven LA, van Wanroij JL, Warlé MC, van Weel V, van Well AM, Welten GM, Welten RJ, Wever JJ, Wiersema AM, Wikkeling OR, Willaert WI, Wille J, Willems MC, Willigendaël EM, Wisselink W, Witte ME, Wittens CH, Wolf-de Jonge IC, Yazar O, Zeebregts CJ, van Zeeland ML.

REFERENCES

1. Armon MP, Wenham PW, Whitaker SC, Gregson RH, Hopkinson BR. Common iliac artery aneurysms in patients with abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 1998;15(3):255-7.
2. Buck DB, Bensley RP, Darling J, Curran T, McCallum JC, Moll FL, et al. The effect of endovascular treatment on isolated iliac artery aneurysm treatment and mortality. *J Vasc Surg.* 2015;62(2):331-5.
3. Filardo G, Powell JT, Martinez MA, Ballard DJ. Surgery for small asymptomatic abdominal aortic aneurysms. *Cochrane Database Syst Rev.* 2015(2):CD001835.
4. Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. *J Vasc Surg.* 2018;67(1):2-77 e2.
5. Wanhainen A, Verzini F, Van Herzele I, Allaire E, Bown M, Cohnert T, et al. European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. *Eur J Vasc Endovasc Surg.* 2018.
6. Williams SK, Campbell WB, Earnshaw JJ. Survey of management of common iliac artery aneurysms by members of the Vascular Society of Great Britain and Ireland. *Ann R Coll Surg Engl.* 2014;96(2):116-20.
7. www.dica.nl/dsaa. Accessed July 1, 2018.
8. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol.* 2008;61(4):344-9.
9. Copeland GP, Jones D, Walters M. POSSUM: a scoring system for surgical audit. *Br J Surg.* 1991;78(3):355-60.
10. Boules TN, Selzer F, Stanziale SF, Chomic A, Marone LK, Dillavou ED, et al. Endovascular management of isolated iliac artery aneurysms. *J Vasc Surg.* 2006;44(1):29-37.
11. Tomee SM, Lijftogt N, Vahl A, Hamming JF, Lindeman JHN. A registry-based rationale for discrete intervention thresholds for open and endovascular elective abdominal aortic aneurysm repair in female patients. *J Vasc Surg.* 2018;67(3):735-9.
12. Lijftogt N, Vahl AC, Wilschut ED, Elsmann BHP, Amodio S, van Zwet EW, et al. Adjusted Hospital Outcomes of Abdominal Aortic Aneurysm Surgery Reported in the Dutch Surgical Aneurysm Audit. *Eur J Vasc Endovasc Surg.* 2017;53(4):520-32.
13. Santilli SM, Wernsing SE, Lee ES. Expansion rates and outcomes for iliac artery aneurysms. *J Vasc Surg.* 2000;31(1 Pt 1):114-21.
14. Krupski WC, Selzman CH, Florida R, Strecker PK, Nehler MR, Whitehill TA. Contemporary management of isolated iliac aneurysms. *J Vasc Surg.* 1998;28(1):1-11; discussion -3.
15. Huang Y, Gloviczki P, Duncan AA, Kalra M, Hoskin TL, Oderich GS, et al. Common iliac artery aneurysm: expansion rate and results of open surgical and endovascular repair. *J Vasc Surg.* 2008;47(6):1203-10; discussion 10-1.
16. Pitoulias GA, Donas KP, Schulte S, Horsch S, Papadimitriou DK. Isolated iliac artery aneurysms: endovascular versus open elective repair. *J Vasc Surg.* 2007;46(4):648-54.
17. Chaer RA, Barbato JE, Lin SC, Zenati M, Kent KC, McKinsey JF. Isolated iliac artery aneurysms: a contemporary comparison of endovascular and open repair. *J Vasc Surg.* 2008;47(4):708-13.
18. Patel NV, Long GW, Cheema ZF, Rimar K, Brown OW, Shanley CJ. Open vs. endovascular repair of isolated iliac artery aneurysms: A 12-year experience. *J Vasc Surg.* 2009;49(5):1147-53.

19. Horejs D, Gilbert PM, Burstein S, Vogelzang RL. Normal aortoiliac diameters by CT. *J Comput Assist Tomogr.* 1988;12(4):602-3.
20. Hernan MA, Robins JM. *Causal Inference.* February 11, 2018. https://cdn1.sph.harvard.edu/wp-content/uploads/sites/1268/2018/02/hernanrobins_v1.10.34.pdf, Accessed July 1, 2018.

SUPPLEMENTS

Supplemental table 1. Definitions of complications registered in the DSAA registry

| | |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Abdominal | Abdominal abscess, abdominal sepsis, ileus, spleen injury, bowel ischemia, bowel injury, stoma placement, other abdominal complications |
| Arterial occlusion | (major) amputation, renal artery occlusion, other arterial occlusion (including trash foot) |
| Prosthesis-/reconstruction related | Prosthesis infection, Prosthesis migration, other prosthesis-/reconstruction related complications |
| Wound | Deep wound infection, fascia dehiscence, other wound complications |
| Cardiac | Myocardial infarction, cardiac decompensation (failure), cardiac rhythm disturbances, other cardiac complications |
| Pulmonary | Pneumonia, pulmonary embolism, pneumothorax, other pulmonary complications |
| Neurological | Cerebrovascular accident, paraplegia, delirium, other neurological complications |
| Renal | Renal insufficiency requiring hemodialysis |
| Rebleeding | Rebleeding |
| Infection | Infections other than pulmonary and surgical |
| Other | Other postoperative complications |

Supplemental table 2. Patient characteristics according to POSSUM

| | Total (n = 851) | Elective (n = 713) | Rupture (n = 102) | Symptomatic (n = 36) |
|--------------------------------------------------------|--------------------|-----------------------|----------------------|-------------------------|
| Age | | | | |
| - <61 | 82 (9.6%) | 72 (10.1%) | 5 (4.9%) | 5 (13.9%) |
| - 61 - 70 | 275 (32.3%) | 238 (33.4%) | 28 (27.5%) | 9 (25%) |
| - >70 | 494 (58.0%) | 403 (56.5%) | 69 (67.6%) | 22 (61.1%) |
| - Missing (%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Cardiac disease | | | | |
| - No abnormalities | 385 (45.2%) | 326 (45.7%) | 43 (42.2%) | 16 (44.4%) |
| - Diuretic, digoxin, med. for angina or hypertension | 357 (42.0%) | 304 (42.6%) | 39 (38.2%) | 14 (38.9%) |
| - Peripheral oedema, warfarin, borderline cardiomegaly | 73 (8.6%) | 60 (8.4%) | 10 (9.8%) | 3 (8.3%) |
| - Raised JVP, cardiomegaly | 17 (2.0%) | 14 (2.0%) | 1 (1.0%) | 2 (5.6) |
| - Missing (%) | 19 (2.2%) | 9 (1.3%) | 9 (8.8%) | 1 (2.8%) |
| Pulmonary disease | | | | |
| - No dyspnoea | 655 (77.0%) | 554 (77.7%) | 76 (74.5%) | 25 (69.4%) |
| - Dyspnoea during exercise | 141 (16.6%) | 124 (17.4%) | 11 (10.8%) | 6 (16.7%) |
| - Disabling dyspnoea | 26 (3.1%) | 25 (3.5%) | 1 (1.0%) | 0 (0%) |
| - Dyspnoea at rest | 6 (0.7%) | 4 (0.6%) | 1 (1.0%) | 1 (2.8%) |
| - Missing (%) | 23 (2.7%) | 6 (0.8%) | 13 (12.7%) | 4 (11.1%) |
| Preoperative ECG | | | | |
| - No abnormalities | 401 (47.1%) | 355 (49.8%) | 33 (32.4%) | 13 (36.1%) |
| - Atrial fibrillation | 66 (7.8%) | 53 (7.4%) | 9 (8.8%) | 4 (11.1%) |
| - Other abnormal rhythm, Q or ST/T wave changes | 276 (32.2%) | 232 (32.5%) | 34 (33.3%) | 10 (27.8%) |
| - No preoperative ECG done | 105 (12.3%) | 72 (10.1%) | 25 (24.5%) | 8 (22.2%) |
| - Missing (%) | 3 (0.4%) | 1 (0.1%) | 1 (1.0%) | 1 (2.8%) |

| | Total (n = 851) | Elective (n = 713) | Rupture (n = 102) | Symptomatic (n = 36) |
|------------------------------|----------------------------|-------------------------------|------------------------------|---------------------------------|
| Systolic BP (mmHg) | | | | |
| - 110 - 129 | 206 (24.2%) | 181 (25.4%) | 17 (16.7%) | 8 (22.2%) |
| - 130 - 170 or 100 - 109 | 522 (61.3%) | 466 (65.4) | 34 (33.3%) | 22 (61.1%) |
| - >170 or 90 - 99 | 62 (7.3%) | 42 (5.9%) | 17 (16.7%) | 3 (8.3%) |
| - <90 | 31 (3.6%) | 2 (0.3%) | 28 (27.5%) | 1 (2.8%) |
| - Missing (%) | 30 (3.5%) | 22 (3.1%) | 6 (5.9%) | 2 (5.6%) |
| Pulse rate (bpm) | | | | |
| - 50 - 80 | 522 (64.9%) | 495 (69.4%) | 36 (35.3) | 21 (58.3%) |
| - 81 - 100 or 40 - 49 | 213 (25.0%) | 167 (23.4%) | 32 (31.4%) | 14 (38.9%) |
| - 101 - 120 | 37 (4.3%) | 20 (2.8%) | 17 (16.7%) | 0 (0%) |
| - >120 or <40 | 9 (1.1%) | 3 (0.4%) | 6 (5.9%) | 0 (0%) |
| - Missing (%) | 40 (4.7%) | 28 (3.9%) | 11 (10.8%) | 1 (2.8%) |
| Haemoglobin (g/dl) | | | | |
| - 13.0 - 16.0 | 522 (61.3%) | 479 (67.2%) | 22 (21.6%) | 21 (58.3%) |
| - 11.5 - 12.9 or 16.1 - 17.0 | 193 (22.7%) | 155 (21.7%) | 30 (29.4%) | 8 (22.2%) |
| - 10.0 - 11.4 or 17.1 - 18.0 | 65 (7.6%) | 38 (5.3%) | 23 (22.5%) | 4 (11.1%) |
| - <10.0 or >18.0 | 56 (6.6%) | 28 (3.9%) | 25 (24.5%) | 3 (8.3%) |
| - Missing (%) | 15 (1.8%) | 13 (1.8%) | 2 (2.0%) | 0 (0.0%) |
| WBC count (/nL) | | | | |
| - 4.0 - 10.0 | 397 (46.7%) | 354 (49.6%) | 25 (24.5%) | 18 (50.0%) |
| - 10.1 - 20.0 or 3.1 - 3.9 | 169 (19.9%) | 97 (13.6%) | 60 (58.8%) | 12 (33.3%) |
| - >20.0 or <3.1 | 20 (2.4%) | 3 (0.4%) | 13 (12.7%) | 4 (11.1%) |
| - Missing (%) | 265 (31.1%) | 259 (36.3%) | 4 (3.9%) | 2 (5.6%) |
| Sodium (mmol/L) | | | | |
| - >135 | 728 (85.5%) | 618 (86.7%) | 79 (77.5%) | 31 (86.1%) |
| - 131 - 135 | 50 (5.9%) | 30 (4.2%) | 16 (15.7%) | 4 (11.1%) |
| - 126 - 130 | 5 (0.6%) | 2 (0.3%) | 3 (2.9%) | 0 (0%) |
| - <126 | 3 (0.4%) | 2 (0.3%) | 0 (0%) | 1 (2.8%) |
| - Missing (%) | 65 (7.6%) | 5 (8.6%) | 4 (3.9%) | 0 (0%) |
| Potassium (mmol/L) | | | | |
| - 3.5 - 5.0 | 747 (87.8%) | 637 (89.3%) | 78 (76.5%) | 32 (88.9%) |
| - 3.1 - 3.4 or 5.1 - 5.3 | 40 (4.7%) | 25 (3.5%) | 12 (11.8%) | 3 (8.3%) |
| - 2.9 - 3.1 or 5.4 - 5.9 | 11 (1.3%) | 5 (0.7%) | 5 (4.9%) | 1 (2.8%) |
| - <2.9 or >5.9 | 3 (0.4%) | 1 (0.1%) | 2 (2.0%) | 0 (0%) |
| - Missing (%) | 50 (5.9%) | 45 (6.3%) | 5 (4.9%) | 0 (0%) |
| Glasgow Coma Scale | | | | |
| - 15 | 794 (93.3%) | 689 (96.6%) | 73 (71.6%) | 32 (88.9%) |
| - 12 - 14 | 19 (2.2%) | 3 (0.4%) | 14 (13.7%) | 2 (5.6%) |
| - 9 - 11 | 1 (0.1%) | 0 (0%) | 1 (1.0%) | 0 (0%) |
| - <9 | 7 (0.8%) | 2 (0.3%) | 5 (4.9%) | 0 (0%) |
| - Missing (%) | 30 (3.5%) | 19 (2.7%) | 9 (8.8%) | 2 (5.6%) |

Percentages for missing data are based on the total sample. EVAR = endovascular aneurysm repair, ECG = electrocardiogram, BP = blood pressure, WBC = white blood cell, bpm = beats per minute.

Urea is also an item of the physiological POSSUM score but was not available in the DSAA registry.

Supplemental table 3. Distribution of IAA diameter at time of elective IAA repair and ruptured IAA repair

| IAA diameter (mm) | Elective IAA repair, n (%) | | Ruptured IAA repair, n (%) | |
|-------------------|----------------------------|--------------|----------------------------|------------|
| | Per diameter category | Cumulative | Per diameter category | Cumulative |
| < 20 | 4 (0.6%) | 4 (0.6%) | 0 (0.0%) | 0 (0%) |
| 20 - 24 | 6 (0.9%) | 10 (1.4%) | 2 (2.2%) | 2 (2.2%) |
| 25 - 29 | 10 (1.4%) | 20 (2.8%) | 2 (2.2%) | 4 (4.4%) |
| 30 - 34 | 52 (7.4%) | 72 (10.2%) | 3 (3.3%) | 7 (7.8%) |
| 35 - 39 | 140 (19.9%) | 212 (30.0%) | 2 (2.2%) | 9 (10.0%) |
| 40 - 44 | 163 (23.1%) | 375 (53.1%) | 3 (3.3%) | 12 (13.3%) |
| 45 - 49 | 118 (16.7%) | 493 (69.8%) | 2 (2.2%) | 14 (15.6%) |
| 50 - 54 | 100 (14.2%) | 593 (84.0%) | 6 (6.7%) | 20 (22.2%) |
| 55 - 59 | 40 (5.7%) | 633 (89.7%) | 5 (5.6%) | 25 (27.8%) |
| 60 - 64 | 32 (4.5%) | 665 (94.2%) | 16 (17.8%) | 41 (45.6%) |
| 65 - 69 | 11 (1.6%) | 676 (95.8%) | 6 (6.7%) | 47 (52.2%) |
| 70 - 74 | 12 (1.7%) | 688 (97.5%) | 6 (6.7%) | 53 (58.9%) |
| 75 - 79 | 4 (0.6%) | 692 (98.0%) | 4 (4.4%) | 57 (63.3%) |
| 80 - 84 | 6 (0.9%) | 698 (98.9%) | 10 (11.1%) | 67 (74.4%) |
| 85 - 89 | 2 (0.3%) | 700 (99.2%) | 6 (6.7%) | 73 (81.1%) |
| 90 - 94 | 3 (0.4%) | 703 (99.6%) | 6 (6.7%) | 79 (87.8%) |
| 95 - 99 | 0 (0.0%) | 703 (99.6%) | 4 (4.4%) | 83 (92.2%) |
| 100 - 104 | 3 (0.4%) | 706 (100.0%) | 4 (4.4%) | 87 (96.7%) |
| 105 - 109 | 0 (0.0%) | 706 (100.0%) | 1 (1.1%) | 88 (97.8%) |
| 110 - 114 | 0 (0.0%) | 706 (100.0%) | 0 (0.0%) | 88 (97.8%) |
| 115 - 119 | 0 (0.0%) | 706 (100.0%) | 1 (1.1%) | 89 (98.9%) |
| ≥ 120 | 0 (0.0%) | 706 (100.0%) | 1 (1.1%) | 90 (100%) |
| Total | 706 (100%) | 706 (100.0%) | 90 (100%) | 90 (100%) |

Supplemental table 4. Mortality stratified by sex

| | Total | Men | Women | p-value |
|---------------------|----------------|---------------|-------------|---------|
| Elective IAA repair | | | | |
| - total | 9/713 (1.3%) | 8/656 (1.2%) | 1/57 (1.8%) | n.s. |
| - EVAR | 5/536 (0.9%) | 5/502 (1.0%) | 0/34 (0%) | n.s. |
| - OSR | 4/154 (2.6%) | 3/132 (2.3%) | 1/22 (4.5%) | n.s. |
| Ruptured IAA repair | | | | |
| - total | 26/102 (25.5%) | 25/91 (27.5%) | 1/11 (9.1%) | n.s. |
| - EVAR | 10/57 (17.5%) | 10/51 (19.6%) | 0/6 (0%) | n.s. |
| - OSR | 13/40 (32.5%) | 12/35 (34.3%) | 1/5 (20.0%) | n.s. |

n.s.: not significant

Supplemental table 5. Differences between survivors and non-survivors

| | Elective IAA repair | | | Ruptured IAA repair | | |
|-----------------------------------------|---------------------|---------------|---------|---------------------|---------------|---------|
| | Survivors | Non-survivors | p-value | Survivors | Non-survivors | p-value |
| Age | 71.2 ± 8.8 | 76.0 ± 5.6 | 0.08 | 73.3 ± 8.5 | 76.1 ± 8.5 | 0.16 |
| Female sex | 56/704 | 1/9 | 0.53 | 10/76 | 1/26 | 0.28 |
| Cardiac history | 371/695 | 7/9 | 0.19 | 34/69 | 16/24 | 0.16 |
| Respiratory history | 149/698 | 4/9 | 0.11 | 9/71 | 4/18 | 0.29 |
| Malignancy, present or previous | 143/704 | 1/9 | 0.70 | 5/72 | 5/26 | 0.12 |
| Systolic blood pressure (mmHg) | 138.3 ± 18.9 | 142.7 ± 31.3 | 0.24 | 117.3 ± 36.5 | 104.5 ± 39.2 | 0.14 |
| Pulse rate (per minute) | 73.0 ± 13.6 | 72.7 ± 26.5 | 0.25 | 87.2 ± 21.1 | 92.7 ± 26.2 | 0.38 |
| Preoperative serum haemoglobin (mmol/L) | 8.7 ± 1.0 | 8.7 ± 1.0 | 0.79 | 7.3 ± 1.2 | 6.5 ± 1.4 | 0.07 |
| Preoperative serum creatinine (µmol/L) | 99.9 ± 60.8 | 101.2 ± 20.7 | 0.15 | 115.3 ± 40.1 | 162.8 ± 80.1 | 0.003 |
| IAA diameter at time of repair | 45.3 ± 11.5 | 50.4 ± 10.2 | 0.10 | 68.6 ± 21.5 | 70.4 ± 22.0 | 0.76 |

Continuous values are reported as mean ± standard deviation. Statistical significance was tested with the Fisher's exact test, Mann Whitney U test, or unpaired t-test.